According to @StockMKTNewz, Novo Nordisk (NYSE: NVO) is planning to target approximately 15 million new patients as Medicare prepares to include weight loss drugs under its coverage. This strategic move could significantly expand Novo Nordisk's market reach and boost its revenue streams, making it a key development for investors to monitor.

According to @CNBC, shares of Eli Lilly (LLY) and Novo Nordisk (NVO) declined after Donald Trump said he wants GLP-1 drugs priced at $150, pressuring the weight-loss and diabetes drug makers on policy headlines. According to @CNBC, the move came on Oct 17, 2025, after the pricing comment, which raised concerns around U.S. drug pricing for GLP-1 therapies. According to @CNBC, there was no reported immediate impact on cryptocurrencies or the broader crypto market.